| Literature DB >> 33333017 |
Graeme Hewitt1, Valerie Borel1, Sandra Segura-Bayona1, Tohru Takaki1, Phil Ruis1, Roberto Bellelli1, Laura C Lehmann2, Lucia Sommerova3, Aleksandra Vancevska1, Antonia Tomas-Loba4, Kang Zhu5, Christopher Cooper5, Kasper Fugger1, Harshil Patel1, Robert Goldstone1, Deborah Schneider-Luftman1, Ellie Herbert1, Gordon Stamp1, Rachel Brough6, Stephen Pettitt6, Christopher J Lord6, Stephen C West1, Ivan Ahel5, Dragana Ahel5, J Ross Chapman3, Sebastian Deindl2, Simon J Boulton7.
Abstract
Chromatin is a barrier to efficient DNA repair, as it hinders access and processing of certain DNA lesions. ALC1/CHD1L is a nucleosome-remodeling enzyme that responds to DNA damage, but its precise function in DNA repair remains unknown. Here we report that loss of ALC1 confers sensitivity to PARP inhibitors, methyl-methanesulfonate, and uracil misincorporation, which reflects the need to remodel nucleosomes following base excision by DNA glycosylases but prior to handover to APEX1. Using CRISPR screens, we establish that ALC1 loss is synthetic lethal with homologous recombination deficiency (HRD), which we attribute to chromosome instability caused by unrepaired DNA gaps at replication forks. In the absence of ALC1 or APEX1, incomplete processing of BER intermediates results in post-replicative DNA gaps and a critical dependence on HR for repair. Hence, targeting ALC1 alone or as a PARP inhibitor sensitizer could be employed to augment existing therapeutic strategies for HRD cancers.Entities:
Keywords: ALC1; BRCAs; DNA damage repair; DNA gycosylases; PARPs; base excsion repair; chromatin remodeler; homologous recombination defieciency; poly(ADP)-ribosylation; synthetic lethality
Year: 2020 PMID: 33333017 DOI: 10.1016/j.molcel.2020.12.006
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970